Lungs News and Research

RSS

Exercise provides therapeutic benefits, such as easing fatigue during radiation treatments

Doctors have known for quite awhile that exercise plays a role in preventing some cancers. But in a new twist, a researcher at the James C. Wilmot Cancer Center is studying whether exercise provides therapeutic benefits, such as easing fatigue during radiation treatments.

28 Apr 2004

The world's smallest computer made entirely of biological molecules

The world's smallest computer (around a trillion can fit in a drop of water) might one day go on record again as the tiniest medical kit.

28 Apr 2004

$4.5 million contract to develop heart assist devices for infants

The University of Pittsburgh's McGowan Institute for Regenerative Medicine has been awarded a five-year $4.5 million contract from the National Heart, Lung, and Blood Institute to develop a heart assist device for infants.

28 Apr 2004

Philippines tightens SARS screening at all entry points

The Philippine Department of Health (DOH) is assuring the public that there is no immediate threat of Severe Acute Respiratory Syndrome (SARS) in the country despite the new cases found in neighboring China.

28 Apr 2004

$11 million for lung injury research

Northwestern University has received an $11 million Program Project Grant (PPG) from the National Institutes of Health to define the mechanisms that cause changes in the alveolar epithelium during lung injury.

27 Apr 2004

BioTime awarded a research grant for blood plasma volume expander

BioTime, Inc. has announced that it has been awarded a research grant by the National Heart, Lung, and Blood Institute division of the National Institutes of Health (NIH) for use in the development of its HetaCool® blood plasma volume expander following peer review.

27 Apr 2004

FDA mandates approval for all pancreatic enzyme replacements

The Cystic Fibrosis Foundation has announced its support of the Food and Drug Administration's (FDA) requirement that manufacturers of pancreatic enzyme replacements obtain FDA approval for their products within the next four years.

27 Apr 2004

California has set a public health goal for arsenic levels in drinking water

The California Environmental Protection Agency’s Office of Environmental Health Hazard Assessment (OEHHA) today announced the publication of a final Public Health Goal (PHG) for arsenic in drinking water.

27 Apr 2004

Inspire announces positive results in cystic fibrosis study

Inspire Pharmaceuticals, Inc. today announced top-line results in a Phase II study of INS37217 Respiratory in patients with mild cystic fibrosis (CF) lung disease.

27 Apr 2004

Britain wheezes at bottom of European lung league

Data from The European Respiratory Society’s (ERS) new European Lung White Book shows that the death rate from respiratory diseases in the UK is 105 per 100,000 people, which is twice the EU average. The only countries with a higher rate are former Soviet Union countries - Kyrgyzstan, Kazakhstan, Turkmenistan and Uzbekistan – and Ireland.

27 Apr 2004

How clean are your lungs?

The airways that conduct air into and out of the lung contain secretions - mucus - that trap inhaled particles. These are removed from the lung by a process called mucociliary clearance that moves the mucus, dead cells and inhaled particles and microorganisms towards the throat from where they are swallowed.

27 Apr 2004

Clinical trial of enzyme replacement therapy for the treatment of Gaucher disease

Transkaryotic Therapies, Inc. today announced that it has initiated a clinical trial to evaluate the safety and clinical activity of GA-GCB, its enzyme replacement therapy for the treatment of Gaucher disease.

26 Apr 2004

New cancer drug Tarceva - a breakthrough with significant survival benefit in patients with advanced lung cancer

OSI Pharmaceuticals, Inc., Genentech, Inc., and Roche today announced that a Phase III study of Tarceva™ (erlotinib HCl), an investigational HER1/EGFR-inhibitor agent in previously treated patients with non-small cell lung cancer (NSCLC), met its primary endpoint of improving overall survival, with patients receiving Tarceva™ living longer than those in the placebo arm of the study.

26 Apr 2004

The cancer death rate for African-American males would drop by nearly two-thirds if their exposure to tobacco smoke was eliminated

The overall cancer death rate for African-American males would drop by nearly two-thirds -- without any other intervention -- if their exposure to tobacco smoke was eliminated, a new study suggests.

25 Apr 2004

Severe Acute Respiratory Syndrome (SARS) overview

Severe Acute Respiratory Syndrome (SARS) is an atypical form of pneumonia that first appeared in November 2002 in Guangdong Province, China.

24 Apr 2004

The donor heart pool could be expanded by including undersized hearts

The donor heart pool could be expanded by including undersized hearts, according to a study presented today at the International Society of Heart and Lung Transplantation.

24 Apr 2004

Spice turmeric corrects the cystic fibrosis defect

Scientists at The Hospital for Sick Children (Sick Kids) and Yale University School of Medicine have found that a compound in the spice turmeric corrects the cystic fibrosis defect in mice. This research is reported in the April 23, 2004 issue of the journal Science.

24 Apr 2004

Respiratory syncytial virus, a common cold virus, can act as a 'hit and hide' virus

An international team of researchers has discovered that respiratory syncytial virus (RSV), a common cold virus causing bronchiolitis in children, can act as a 'hit and hide' virus. It was thought that the virus could only survive in the body for a few days, but these new results show that the virus can survive for many months or years, perhaps causing long-term effects on health, such as damage to the lungs.

23 Apr 2004

CellCept linked to reduced cancer incidence

A study presented today at an international transplant meeting showed that heart transplant patients treated with the immunosuppressant CellCeptÒ (mycophenolate mofetil) in standard immunosuppressive regimens had a significantly lower risk of developing cancer compared to those receiving non-CellCept-based treatment regimens.

23 Apr 2004

Clinical trial of curcumin in people with cystic fibrosis

Cystic Fibrosis Foundation Therapeutics, Inc. (CFFT), the nonprofit drug discovery and development affiliate of the Cystic Fibrosis Foundation, today announced that it is funding a clinical trial of curcumin in people with cystic fibrosis (CF).

22 Apr 2004